FoundationOne CDx

Categories

Description

A comprehensive genomic profiling test for advanced cancer patients with solid tumors.

Summary

FoundationOne CDx is a next-generation sequencing based in vitro diagnostic test designed for advanced cancer patients with solid tumors. It utilizes FFPE tissue samples to analyze 324 genes as well as genomic signatures, helping to identify the genomic alterations driving a patient's cancer. This information can match patients with relevant targeted therapies, immunotherapies, and clinical trial options, providing a personalized approach to cancer treatment.

Use Cases

• Identifying genomic alterations in a patient's solid tumor to guide targeted therapy selection.
• Matching advanced cancer patients with relevant clinical trials based on their tumor's genomic profile.